AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer
February 23, 2026
Technology
-
-
NetworkNews Audio Announces Audio Press Release (APR) Discussing Growing Investor Attention on Companies Holding Clinical-Stage Portfolios
February 23, 2026
-
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
February 23, 2026
-
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
February 23, 2026
-
Broadridge to Participate in Upcoming Investor Events
February 23, 2026
-
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
February 20, 2026
-
ISG to Study Cloudera Ecosystem Providers
February 20, 2026
-
Freight Technologies Completes ISO 9001:2015 Annual Audit
February 20, 2026
-
Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development
February 20, 2026
-
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Announces Expanded IP Coverage, Strengthening Position in Biotech Evolution
February 20, 2026
-
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval
February 20, 2026
-
SEALSQ and Quobly Mutually Agree to Halt Discussions Regarding a Potential Majority Investment or Acquisition by SEALSQ
February 20, 2026
-
Society Pass Incorporated (Nasdaq: SOPA) and NusaTrip Incorporated (Nasdaq: NUTR) Respond to Nasdaq/SEC Questions Regarding Status of Trading of NUTR’s Securities; NusaTrip’s Operations Remain Normal and Unaffected by Trading Suspension
February 20, 2026
-
Kane Biotech Announces Publication of revyve® Wound Gel Article in the International Wound Journal
February 20, 2026
-
Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine(TM), with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects
February 19, 2026
-
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA(TM) (bevacizumab gamma) in Switzerland
February 19, 2026